Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
Subscribe To Our Newsletter & Stay Updated